# C_2015280EN.01000901.xml

| 25.8.2015 | EN | Official Journal of the European Union | C 280/9 |
| --- | --- | --- | --- |

25.8.2015

EN

Official Journal of the European Union

C 280/9

---

Prior notification of a concentration

(Case M.7716 — Pfizer/GSK MenACWY Business)

Candidate case for simplified procedure

(Text with EEA relevance)

(2015/C 280/10)

| 1. | On 17 August 2015 the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Pfizer Ireland Pharmaceuticals (‘Pfizer’, Ireland) controlled by Pfizer Inc. (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the assets constituting the Nimenrix and Mencevax Meningococcal ACWY vaccines business (the ‘MenACWY vaccines business’) of GlaxoSmithKline Biologicals SA (‘GSK’, Belgium), by way of purchase of assets. |
| --- | --- |

1.

On 17 August 2015 the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertaking Pfizer Ireland Pharmaceuticals (‘Pfizer’, Ireland) controlled by Pfizer Inc. (USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the assets constituting the Nimenrix and Mencevax Meningococcal ACWY vaccines business (the ‘MenACWY vaccines business’) of GlaxoSmithKline Biologicals SA (‘GSK’, Belgium), by way of purchase of assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   Pfizer: manufacturing of pharmaceutical products including pharmaceutical ingredients, solid dose pharmaceuticals, sterile injectables, nutritionals, vaccines and biopharmaceuticals, commercial human prescription, animal health and consumer health products businesses,
  —   GSK’s MenACWY vaccines business: two Meningococcal ACWY vaccines, Mencevax, a polysaccharide MenACWY vaccine, and Nimenrix, a conjugate MenACWY vaccine. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   Pfizer: manufacturing of pharmaceutical products including pharmaceutical ingredients, solid dose pharmaceuticals, sterile injectables, nutritionals, vaccines and biopharmaceuticals, commercial human prescription, animal health and consumer health products businesses,

Pfizer

—   GSK’s MenACWY vaccines business: two Meningococcal ACWY vaccines, Mencevax, a polysaccharide MenACWY vaccine, and Nimenrix, a conjugate MenACWY vaccine.

GSK’s MenACWY vaccines business

Mencevax

Nimenrix

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7716 — Pfizer/GSK MenACWY Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7716 — Pfizer/GSK MenACWY Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---